Topical Hydroquinone for Hyperpigmentation: A Narrative Review
- PMID: 38106810
- PMCID: PMC10723018
- DOI: 10.7759/cureus.48840
Topical Hydroquinone for Hyperpigmentation: A Narrative Review
Abstract
Topical hydroquinone (HQ) has been used for decades to treat disorders of hyperpigmentation such as melasma, post-inflammatory hyperpigmentation, and solar lentigines. Additionally, it has been used as a skin-lightening agent for cosmetic purposes. Multiple studies have shown it to be effective in treating hyperpigmentation, though it is not without side effects. Currently, HQ is not approved for over-the-counter use in the United States. Its use is also banned in other countries, including Japan, Australia, and the European Union. Hyperpigmentation disorders affect individuals worldwide. Patients with these disorders are frequently seen in medical practices. Hyperpigmentation disorders can significantly negatively impact a person's quality of life, and agents that treat hyperpigmentation can improve patient outcomes. A comprehensive literature search was performed on HQ as a treatment for skin hyperpigmentation disorders. A literature review revealed that HQ is an effective compound for treating hyperpigmentation disorders and can be combined with other therapies for enhanced results. Evidence exists to support HQ as a topical therapy for skin hyperpigmentation. HQ is not without side effects and should be prescribed by trained professionals who can educate patients on usage. HQ can be used in pharmaceutical regimens to treat hyperpigmentation disorders.
Keywords: cosmetics; hydroquinone; hyperpigmentation; melasma; skin lightening.
Copyright © 2023, Fabian et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
References
-
- Schwartz C, Jan A, Zito PM. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2023. Hydroquinone. - PubMed
-
- Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. Taylor A, Pawaskar M, Taylor SL, Balkrishnan R, Feldman SR. J Cosmet Dermatol. 2008;7:164–168. - PubMed
-
- Psychological disturbances in patients with pigmentary disorders: a cross-sectional study. Dabas G, Vinay K, Parsad D, Kumar A, Kumaran MS. J Eur Acad Dermatol Venereol. 2020;34:392–399. - PubMed
-
- Mechanism of photographic development. II. Development by hydroquinone. James T. https://pubs.acs.org/doi/pdf/10.1021/j150397a006 J Phys Chem. 1940;44:42–57.
Publication types
LinkOut - more resources
Full Text Sources